Ranchi News Desk

Key players such as Roche, Novartis, and others are developing therapies to enhance treatment modalities in the Atypical Hemolytic Uremic Syndrome market

 Breaking News
  • No posts were found

Key players such as Roche, Novartis, and others are developing therapies to enhance treatment modalities in the Atypical Hemolytic Uremic Syndrome market

November 26
01:30 2021
Key players such as Roche, Novartis, and others are developing therapies to enhance treatment modalities in the Atypical Hemolytic Uremic Syndrome market
Atypical Hemolytic Uremic Syndrome Market
The current Atypical Hemolytic Uremic Syndrome therapeutic landscape is dominated by approved therapies such as Soliris and Ultomiris.

DelveInsight’s Atypical Hemolytic Uremic Syndrome market report thoroughly explains the Atypical Hemolytic Uremic Syndrome historical and forecasted epidemiology and the Atypical Hemolytic Uremic Syndrome market trends in the 7MM. 

Some of the Important Findings from the Atypical Hemolytic Uremic Syndrome Market Report

  • According to the aHUS foundation, Atypical Hemolytic Uremic Syndrome has the “ultra-rare” designation, which is reserved for diseases that affect fewer than 20 people per million. 

  • As per DelveInsight estimates, the total aHUS prevalent cases were 7.0 thousand in the 7MM in 2020, which is further expected to increase by 2030.

  • According to the estimates, the total aHUS diagnosed cases were over 2 thousand in the US in 2020.

  • The key players in the aHUS market include Roche, Novartis, and others.

  • Key aHUS therapies in the pipeline include Iptacopan (LNP023), Crovalimab (RG6107, SKY59), and others.

  • Iptacopan, also known as LNP023, is a first-in-class, orally-administered, small-molecule, potent, and highly selective factor B (FB) inhibitor, an essential serine protease of the complement cascade’s alternative pathway.

Request for a sample to know more @ Atypical Hemolytic Uremic Syndrome Market Outlook

Atypical Hemolytic Uremic Syndrome: Overview

Atypical Hemolytic Uremic Syndrome (aHUS) is a disease that causes abnormal blood clots to form in the kidneys’ tiny blood vessels. If these clots restrict or block blood flow, they can cause serious medical problems such as hemolytic anaemia, thrombocytopenia, and kidney failure.

Atypical Hemolytic Uremic Syndrome Epidemiology Segmentation

The Atypical Hemolytic Uremic Syndrome report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

  • Atypical Hemolytic Uremic Syndrome Total Prevalent Cases

  • Atypical Hemolytic Uremic Syndrome Total Diagnosed Cases

  • Atypical Hemolytic Uremic Syndrome Total Age Group-Specific Cases

  • Atypical Hemolytic Uremic Syndrome Total Treated Cases

Atypical Hemolytic Uremic Syndrome Treatment Landscape

The current aHUS treatment option includes Conventional Therapy (Plasma Therapy, Dialysis, diuretics, Anti-hypertensive). Some FDA-approved drugs, such as Soliris (eculizumab) and Ultomiris (ravulizumab), by Alexion Pharmaceuticals, are also for aHUS treatment.

Atypical Hemolytic Uremic Syndrome Market Outlook

The current Atypical Hemolytic Uremic Syndrome therapeutic landscape is dominated by approved therapies such as Soliris and Ultomiris. The introduction of new developmental candidates such as Iptacopan (LNP023), Crovalimab (RG6107, SKY59), and others currently in the pipeline are expected to impact the Atypical Hemolytic Uremic Syndrome market during the forecast period (2021-2030).

Get a detailed analysis of the market @ Atypical Hemolytic Uremic Syndrome Therapeutic Market

Atypical Hemolytic Uremic Syndrome Pipeline Therapies and Key Companies 

Iptacopan (LNP023): Novartis

Crovalimab (RG6107, SKY59): Roche

Table of Contents 

1.

Key Insights

2.

Report Introduction

3.

Atypical Hemolytic Uremic Syndrome (aHUS) Market Overview at a Glance

4.

Executive Summary of Atypical Hemolytic Uremic Syndrome (aHUS)

5.

aHUS Epidemiology and Market Methodology

6.

aHUS Disease Background and Overview

7.

Diagnosis and Differential Diagnosis of Atypical Hemolytic Uremic Syndrome

8.

aHUS Diagnostic Guidelines

9.

Current Treatment Practices of Atypical Hemolytic Uremic Syndrome

10.

aHUS Treatment Guidelines

11.

Conclusion

12.

aHUS Epidemiology and Patient Population

13.

aHUS Patient Journey

14.

Key Endpoints in Atypical Hemolytic Uremic Syndrome (aHUS) Clinical Trials

15.

aHUS Marketed Therapies

16.

aHUS Emerging Therapies

17.

Atypical Hemolytic Uremic Syndrome: 7 Major Market Analysis

18.

aHUS Market Access and Reimbursement

19.

KOL Views

20.

aHUS Market Drivers

21.

aHUS Market Barriers

22.

SWOT Analysis

23.

aHUS Unmet Needs

24.

Appendix

25.

DelveInsight Capabilities

26.

Disclaimer

27.

About DelveInsight

Get in touch with our business executive for Healthcare Due Diligence Services

Related Reports

Warm Autoimmune Hemolytic Anemia Market

DelveInsight’s ‘Warm Autoimmune Hemolytic Anemia (WAIHA) – Market Insights, Epidemiology and Market Forecast-2030′ report deliver an in-depth understanding of the disease, historical &forecasted epidemiology, as well as the market trends of WAIHAs in the 7MM.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/

Related Articles

Recent Posts

Lip Care Products Market Growth Is Majorly Driven By Increasing Beauty Consciousness Among Women And Men Till 2025 | Million Insights

Read Full Article